Context Therapeutics Investor Presentation Deck
September 2022, 25 slides
  1. Context Therapeutics
  2. Related Decks
  3. Investor Presentation Decks
eta ell | Context Therapeutics
forward looking statement | Context Therapeutics
context therapeutics overview | Context Therapeutics
pipeline | Context Therapeutics
ona progesterone receptor antagonist | Context Therapeutics
extended release ona | Context Therapeutics
clinical development strategy blocking cancer growth by combining and therapies stimulus estrogen progesterone | Context Therapeutics
ona evaluation in breast cancer clinical trials adjuvant window of her ona post i developing ona as an add on to therapy across treatment lines | Context Therapeutics
ona evaluation in gynecologic clinical trials developing ona as an add on to therapy across gynecologic cancers | Context Therapeutics
ona combination clinical trial clinical trial collaboration with | Context Therapeutics
rationale for clinical trial collaboration sea men context | Context Therapeutics
phase trial designed to evaluate combination efficacy and tolerability patient population prior therapy with inhibitor required phase dose patients phase patients | Context Therapeutics
antibody program | Context Therapeutics
proteins tight junctions regulate cell barrier and permeability tight junction structure proteins constitute a structural core of along with junction adhesion molecule jam and over proteins have been characterized including cancer of protein expression and function occurs in multiple diseases | Context Therapeutics
many proteins are associated with disease | Context Therapeutics
is an emerging oncology target is a tumor specific protein that is present at high surface density across adult and pediatric cancers selectivity is required to avoid off target liabilities identified in murine knockout studies with pancreas kidney pancreas and ear gut establishes proof of concept for of patients who received car vaccine showed a partial response in an ongoing study in solid tumors elevated and lipase were noted side effects | Context Therapeutics
prevalence in cancer gastric lin | Context Therapeutics
antibody program candidate selection on track for i yen | Context Therapeutics
our antibodies display high selectivity for log log | Context Therapeutics
antibody library log a a | Context Therapeutics
corporate | Context Therapeutics
focus on execution spark experienced leadership team galera | Context Therapeutics
recent and key anticipated milestones ona granulosa cell phase preliminary data | Context Therapeutics
investment highlights a large unmet need female cancers high value targets progesterone receptor and strong financial strength | Context Therapeutics
in i female cancers as context therapeutics | Context Therapeutics
See More
Context Therapeutics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Ovarian
Metastatic
Clinical trial
Clinical development
Related decks
Allarity Therapeutics
Investor Conference
September 2022
Genelux
Investor Presentation
July 2023
Immatics
Investor Presentation
November 2023
RayzeBio
IPO
September 2023
TCR2 Therapeutics
Results
September 2022
Alkermes
Investor Day
March 2021
Genelux
Investor Presentation
February 2024
Genelux
Investor Presentation
October 2023
Allarity Therapeutics
Investor Conference
September 2022
Genelux
Investor Presentation
July 2023
Immatics
Investor Presentation
November 2023
RayzeBio
IPO
September 2023
TCR2 Therapeutics
Results
September 2022
Alkermes
Investor Day
March 2021
Genelux
Investor Presentation
February 2024
Genelux
Investor Presentation
October 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io